{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:08:33Z","timestamp":1788300513697,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T02:18:45Z","timestamp":1708136325000},"page":"37-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study"],"prefix":"10.1016","volume":"236","author":[{"given":"Yongkang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhi","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangli","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.02.010_bb0005","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2024.02.010_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.02.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30117-0","article-title":"Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study","volume":"8","author":"Song","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.thromres.2024.02.010_bb0020","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.02.010_bb0025","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/j.jvs.2014.12.006","article-title":"Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"Introduction. J Vasc Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0030","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"Surgery or endovascular therapy for chronic limb-threatening ischemia","volume":"387","author":"Farber","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"208\u201315","key":"10.1016\/j.thromres.2024.02.010_bb0035","article-title":"Variability of antiplatelet response in patients with peripheral artery disease","volume":"77","author":"Majumdar","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.122.062762","article-title":"Indobufen or aspirin on top of Clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point-blinded","volume":"147","author":"Wu","year":"2023","journal-title":"Noninferiority Trial. Circulation."},{"key":"10.1016\/j.thromres.2024.02.010_bb0045","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.2018","article-title":"Contemporary time trends in use of antiplatelet agents among patients with acute coronary syndrome and comorbid diabetes mellitus or chronic kidney disease","volume":"37","author":"Desai","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2024.02.010_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.09.010","article-title":"Influence of diabetes mellitus and cigarette smoking on variability of the clopidogrel-induced antiplatelet effect and efficacy of active management of the target P2Y12 reaction unit range in patients undergoing neurointerventional procedures","volume":"25","author":"Nakagawa","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2024.02.010_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2011.127","article-title":"Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects","volume":"90","author":"Simon","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1358836X9800300312","article-title":"Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel","volume":"3","author":"Schror","year":"1998","journal-title":"Vasc. Med."},{"key":"10.1016\/j.thromres.2024.02.010_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCGENETICS.115.001318","article-title":"Pharmacogenetics of clopidogrel: an unresolved issue","volume":"9","author":"Pereira","year":"2016","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"552\u20137","key":"10.1016\/j.thromres.2024.02.010_bb0070","article-title":"Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention","volume":"21","author":"Johnson","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.thromres.2024.02.010_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/cpt.519","article-title":"Clopidogrel pharmacogenetics: beyond candidate genes and genome-wide association studies","volume":"101","author":"Lewis","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0080","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/jcph.769","article-title":"The metabolism of clopidogrel: CYP2C19 is a minor pathway","volume":"56","author":"Ford","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.thromres.2024.02.010_bb0090","first-page":"10","article-title":"Artificial-intelligence-assisted discovery of genetic factors for precision medicine of antiplatelet therapy in diabetic peripheral artery disease","author":"Yeh","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.thromres.2024.02.010_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.576046","article-title":"Cyp2C19*2 polymorphism related to clopidogrel resistance in patients with coronary heart disease, especially in the Asian population: a systematic review and meta-analysis","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.thromres.2024.02.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106798","article-title":"Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic stroke patients treated with clopidogrel in China: a meta-analysis","volume":"31","author":"Yan","year":"2022","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2024.02.010_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","author":"Leunissen","year":"2016","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0110","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jvs.2017.07.065","article-title":"Review of aspirin and clopidogrel resistance in peripheral arterial disease","volume":"66","author":"Guirgis","year":"2017","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00228-022-03346-7","article-title":"Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review","volume":"78","author":"Huang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0120","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.jacc.2013.03.036","article-title":"Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity","volume":"61","author":"Spiliopoulos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jvs.2014.03.293","article-title":"Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease","volume":"60","author":"Guo","year":"2014","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0130","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0135","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00270-013-0577-3","article-title":"Clopidogrel responsiveness in patients undergoing peripheral angioplasty","volume":"36","author":"Pastromas","year":"2013","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0140","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2217\/pgs-2016-0056","article-title":"Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty","volume":"17","author":"Diaz-Villamarin","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.thromres.2024.02.010_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejvs.2019.02.011","article-title":"CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb Ischaemia","volume":"58","author":"Lee","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0150","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.02.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008069","article-title":"Impact of procedural bleeding in peripheral artery disease: an analysis from EUCLID trial","volume":"12","author":"Kansal","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2024.02.010_bb0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","author":"Kerneis","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2024.02.010_bb0165","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1253\/circj.CJ-15-0546","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease","volume":"79","author":"Nishi","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0170","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1253\/circj.CJ-13-1216","article-title":"Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy","volume":"78","author":"Pelliccia","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0175","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0180","series-title":"What Is Population Ageing and How Is it Measured","author":"Hongyan Cui","year":"2023"},{"key":"10.1016\/j.thromres.2024.02.010_bb0185","unstructured":"Contributors W. List of Countries by Age Structure. Wikipedia, The Free Encyclopedia."},{"key":"10.1016\/j.thromres.2024.02.010_bb0190","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(22)01546-X","article-title":"The path to healthy ageing in China: a Peking University-lancet commission","volume":"400","author":"Chen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2024.02.010_bb0195","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.2047-6310.2012.00064.x","article-title":"Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity","volume":"7","author":"Cole","year":"2012","journal-title":"Pediatr. Obes."},{"key":"10.1016\/j.thromres.2024.02.010_bb0200","unstructured":"Body Mass Index (BMI). World Health Organization."},{"key":"10.1016\/j.thromres.2024.02.010_bb0205","first-page":"362","article-title":"Lower extremity peripheral artery disease: diagnosis and treatment","volume":"99","author":"Firnhaber","year":"2019","journal-title":"Am. Fam. Physician"},{"issue":"39","key":"10.1016\/j.thromres.2024.02.010_bb0210","first-page":"763","volume":"2018","author":"Aboyans","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0215","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.thromres.2024.02.010_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"10.1016\/j.thromres.2024.02.010_bb0225","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ccd.27453","article-title":"Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease","volume":"91","author":"Yeo","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"94","key":"10.1016\/j.thromres.2024.02.010_bb0230","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0235","first-page":"68","article-title":"The validation and application of a novel CYP2C19 genotyping approach based on capillary electrophoresis in Chinese Han population","author":"Chen","year":"2022","journal-title":"Clin. Lab."},{"key":"10.1016\/j.thromres.2024.02.010_bb0240","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/iji.12511","article-title":"Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease","volume":"47","author":"Ma","year":"2020","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.thromres.2024.02.010_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2022.08.001","article-title":"CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)","volume":"254","author":"Kranendonk","year":"2022","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0250","article-title":"Predictors of poor outcomes after lower extremity revascularization for acute limb ischemia","author":"Juneja","year":"2023","journal-title":"Vascular"},{"key":"10.1016\/j.thromres.2024.02.010_bb0255","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.avsg.2015.10.004","article-title":"Risk factors for long-term mortality and amputation after open and endovascular treatment of acute limb ischemia","volume":"30","author":"Genovese","year":"2016","journal-title":"Ann. Vasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0260","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","article-title":"Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence","volume":"36","author":"Reinecke","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0265","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jcin.2020.06.059","article-title":"Real-world experience with a paclitaxel-coated balloon in critical limb ischemia: 24-month subgroup outcomes of BIOLUX P-III","volume":"13","author":"Brodmann","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2024.02.010_bb0270","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0034-1393976","article-title":"Overview of classification systems in peripheral artery disease","volume":"31","author":"Hardman","year":"2014","journal-title":"Semin. Intervent. Radiol."},{"key":"10.1016\/j.thromres.2024.02.010_bb0275","doi-asserted-by":"crossref","DOI":"10.1177\/2050312115597087","article-title":"Clinical characteristics of patients with Rutherford category IV, compared with V and VI","volume":"3","author":"Tsuchiya","year":"2015","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.thromres.2024.02.010_bb0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Working group on thrombosis of the European Society of C. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0285","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0035-1564834","article-title":"Platelet function tests","volume":"42","author":"Lordkipanidze","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.02.010_bb0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2023.08.017","article-title":"Plasma protein signatures for high on-treatment platelet reactivity to aspirin and clopidogrel in peripheral artery disease","volume":"230","author":"Baidildinova","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.02.010_bb0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12959-022-00445-4","article-title":"Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study","volume":"21","author":"Kremers","year":"2023","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0300","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejvs.2015.09.020","article-title":"Effect of CYP2C19 polymorphisms on the platelet response to clopidogrel and influence on the effect of high versus standard dose clopidogrel in carotid artery stenting","volume":"51","author":"Gonzalez","year":"2016","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.thromres.2024.02.010_bb0305","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3349\/ymj.2011.52.5.734","article-title":"Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease","volume":"52","author":"Lee","year":"2011","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0310","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.jfma.2022.01.013","article-title":"Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: switch study","volume":"121","author":"Kuo","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.thromres.2024.02.010_bb0315","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1038\/s41598-022-09679-8","article-title":"Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients","volume":"12","author":"Ahmed","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2024.02.010_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236260","article-title":"Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke","volume":"15","author":"Rath","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.thromres.2024.02.010_bb0325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ahj.2013.10.028","article-title":"Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans","volume":"167","author":"Oestreich","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0330","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cpt.1911","article-title":"Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium","volume":"108","author":"Verma","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0335","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","article-title":"Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients","volume":"6","author":"Lewis","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.thromres.2024.02.010_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106631","article-title":"P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment","volume":"31","author":"Fujita","year":"2022","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2024.02.010_bb0345","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1253\/circj.CJ-21-0717","article-title":"Ischemic and bleeding events in PENDULUM patients with high bleeding risk and high platelet reactivity","volume":"86","author":"Iijima","year":"2022","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2024.02.010_bb0350","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv."},{"key":"10.1016\/j.thromres.2024.02.010_bb0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1755-5922.2011.00296.x","article-title":"Clopidogrel \u201cresistance\u201d: where are we now?","volume":"31","author":"Qureshi","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.thromres.2024.02.010_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.686","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy","volume":"8","author":"Alvitigala","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.thromres.2024.02.010_bb0365","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/a-1223-3306","article-title":"Laboratory techniques used to diagnose constitutional platelet dysfunction","volume":"40","author":"Ibrahim-Kosta","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.thromres.2024.02.010_bb0370","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.12.004","article-title":"Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke","volume":"20","author":"Fong","year":"2011","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2024.02.010_bb0375","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165660","article-title":"Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients","volume":"50","author":"Marchini","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.thromres.2024.02.010_bb0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.114.215616","article-title":"Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects","volume":"351","author":"Cleator","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:18:32Z","timestamp":1717251512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":76,"alternative-id":["S0049384824000458"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}